Stellate Ganglion Block Long COVID POTS: 2026 STAR-CO Trial & Autonomic Reset Protocol (Part 2)

Stellate ganglion block Long COVID POTS is no longer a fringe intervention — as of early 2026, it is the subject of the first dedicated placebo-controlled RCT and a formal editorial endorsement in Frontiers in Neuroscience. This is Part 2 of our ongoing coverage. If you are new to this topic, start with our foundational SGB overview before continuing here — the mechanistic groundwork laid there is assumed throughout this update.

Executive Summary: What’s New in 2026

• Alpha #1 — First RCT Now Recruiting: The STAR-CO Trial (NCT07374562), launched February 2026, is the first single-blind randomized controlled trial of SGB vs. placebo specifically for Long COVID. It measures functional status, fatigue, brain fog, and critically — orthostatic tolerance via the NASA Lean Test, making it the most rigorous POTS-relevant SGB study to date.
• Alpha #2 — Institutional Endorsement: A March/April 2026 editorial in Frontiers in Neuroscience (Guo, Reist & Malik, UC Irvine) formally positions SGB as a neuromodulatory intervention for post-viral autonomic dysfunction — the first major journal to do so explicitly. This is a signal, not a proof, but it matters for clinical uptake.
• Alpha #3 — Mechanism Update: New translational data confirms SGB reduces circulating norepinephrine and upregulates serotonin and neuropeptide-Y — a neuroendocrine reset profile that directly interrupts the sympathetic-overdrive → mitochondrial uncoupling cascade driving bioenergetic failure in Long COVID/POTS patients.

The Biological Mechanism: How Stellate Ganglion Block Long COVID POTS Disrupts the Catecholamine–Mito Cascade

To understand why SGB is being pursued for stellate ganglion block Long COVID POTS, you need to understand what SARS-CoV-2 did to the autonomic nervous system — and why standard treatments miss the root architecture.

The stellate ganglion is a cervicothoracic sympathetic ganglion — essentially a relay hub for the fight-or-flight signaling network. In healthy individuals, it cycles normally. In Long COVID, multiple converging pathways appear to lock it in a state of chronic hyperactivation:

1. Viral spike remnants + endothelial senescence: Persistent spike protein fragments drive endothelial cells into a Systemic Pro-inflammatory Secretory Phenotype (SASP), promoting vascular microclots and regional hypoxia. This hypoxic signal feeds back to the sympathetic axis, sustaining the alarm state. For a deeper look at how nattokinase targets these microclots, see our post on nattokinase for Long COVID.
2. Catecholamine storm → mitochondrial uncoupling: Chronic norepinephrine elevation — a hallmark of Long COVID dysautonomia — activates β-adrenergic receptors on mitochondrial membranes. This triggers mitochondrial uncoupling protein 2 (UCP2) upregulation, dissipating the proton gradient across the inner membrane as heat rather than ATP. The result: bioenergetic failure at the cellular level. Cristae swelling on electron microscopy confirms the structural toll.
3. Warburg-like metabolic shift: With oxidative phosphorylation compromised, cells default to glycolysis — a far less efficient ATP pathway. This “Warburg-like” metabolic reprogramming, well-documented in CFS/ME research, is not a choice; it’s a survival response to a broken electron transport chain. The downstream result is lactic acidosis, reduced PEM threshold, and the characteristic post-exertional crash that defines Long COVID for many executives we hear from.
4. Microglial activation and neuro-inflammation: Sustained sympathetic overdrive also correlates with microglial activation — brain-resident immune cells that, when chronically triggered, produce cytokines degrading cognitive function. This is the mechanism behind Long COVID brain fog, and it connects to why photobiomodulation is being trialed for Long COVID brain fog via a different entry point in the same cascade.

What This Means For You (Plain-English Callout): Your stellate ganglion isn’t just a pain relay. In Long COVID and POTS, it’s a stuck switch — locked in the “on” position after viral injury. Every subsequent symptom — the racing heart, the cognitive fog, the exercise intolerance — flows downstream from that one misconfigured node. SGB is, in essence, a hardware reset. The question is whether a single injection provides durable reconfiguration, or whether it’s a temporary patch on a deeper system fault. That’s exactly what the STAR-CO trial is designed to answer.

The 2026 Evidence Update: STAR-CO Trial & Frontiers Editorial

STAR-CO Trial (NCT07374562) — What We Know So Far

Registered and launched in early 2026, the STAR-CO Trial (Stellate ganglion block for post-COVID syndrome) is the first single-blind RCT to directly test SGB against a sham procedure specifically in Long COVID patients. Here are the key parameters:

• Design: Single-blind, parallel-group RCT; 40 participants; sponsor: CIUSSS-MCQ (Québec, Canada)
• Active arm: Single right-sided SGB under ultrasound guidance — 7 mL of 0.5% bupivacaine, positioned between the longus colli muscle and carotid artery. Correct placement confirmed by Claude Bernard-Horner syndrome appearance.
• Placebo arm: 6-8 mL normal saline injected into the right sternocleidomastoid muscle — same positioning, same ultrasound guidance, zero ganglionic effect.
• Primary outcomes: Post-COVID Functional Status Scale (PCFS), Fatigue Severity Scale (FSS), Brain Fog Scale (BFS) — all at 4 weeks post-procedure
• Critical secondary outcome: NASA Lean Test for orthostatic intolerance — directly measuring the POTS-relevant autonomic endpoint
• Follow-up: 26 weeks with scheduled evaluations
• Expected completion: February 2027

Clinical significance: The sham design is methodologically sound — participants cannot distinguish their injection from the real procedure. Critically, the STAR-CO protocol excludes prior ME/CFS and fibromyalgia diagnoses (important confounders), which should sharpen the signal for a post-viral autonomic phenotype specifically. The 26-week follow-up is also longer than most prior case series, enabling assessment of durability.

Frontiers in Neuroscience 2026 Editorial: A Turning Point for Institutional Recognition

In March/April 2026, Frontiers in Neuroscience published an editorial by Guo, Reist, and Malik (University of California, Irvine) synthesizing the growing SGB evidence base. Crucially, the editorial explicitly states that “recent clinical observations suggest that autonomic nerve blocks, including SGB, may improve certain Long COVID symptoms” — and frames post-viral autonomic dysfunction as a primary candidate for SGB intervention.

The editorial also references data from Liu et al. showing that SGB treatment produces measurable neurobiological changes: reductions in circulating norepinephrine alongside increases in serotonin and neuropeptide-Y. This is not merely symptom palliation — it represents a shift in the neuroendocrine setpoint, providing the first mechanistic bridge between SGB’s peripheral effect (stellate ganglion blockade) and its reported central benefits (cognitive improvement, HRV normalization). The editorial also notes the growing case series literature at PubMed documenting SGB’s efficacy in Long COVID symptom clusters.

Does SGB Work? The Pre-RCT Evidence Base

Before the STAR-CO data is available, what does the existing evidence say? A retrospective cohort study published in 2024-2025 (Cureus) found that among Long COVID patients receiving SGB, the most commonly improved symptoms were brain fog, fatigue, dizziness, and headache. Approximately 25% of patients reported significant improvement across multiple symptom domains. An earlier PMC case series (PMID 8653406) found 86% of patients reported symptom reduction following SGB treatment. These are not RCT-level proofs — but they define a signal worth testing rigorously, which is exactly what STAR-CO will do.

Clinical Protocol: Updated 2026 Guidance for Stellate Ganglion Block Long COVID POTS

Who Qualifies?

Based on the STAR-CO inclusion/exclusion criteria and current practitioner consensus, appropriate candidates for SGB evaluation include:

• Adults with confirmed or presumed Long COVID ≥12 weeks post-infection
• Documented POTS or orthostatic intolerance (heart rate increase ≥30 bpm on standing or NASA Lean Test)
• Persistent fatigue, brain fog, or dyspnea with functional impairment (PCFS ≥2)
• Failure of or inadequate response to standard first-line autonomic management (beta-blockers, fludrocortisone, increased salt/fluid intake)

Contraindications to Screen For

• Active anticoagulation therapy (bleeding risk at injection site)
• Cardiac conduction abnormalities (risk of bradyarrhythmia)
• Glaucoma (risk of intraocular pressure change)
• Myocardial infarction within 12 weeks
• Known hypersensitivity to bupivacaine or amide local anesthetics
• Emphysema requiring home oxygen
• Pregnancy or breastfeeding

Imaging Guidance: Why Ultrasound Is Now Non-Negotiable

The Frontiers in Neuroscience editorial explicitly notes that “ultrasound-guided SGB has marked a pivotal advancement, proving to be more effective and safer compared to traditional blind injection techniques.” The STAR-CO protocol mandates real-time ultrasound guidance for all injections. For any executive considering this procedure, insisting on ultrasound guidance (rather than fluoroscopy-only or landmark-based technique) is a minimum standard of care in 2026. The needle is positioned between the longus colli muscle and the carotid artery — precision that cannot be reliably achieved without live imaging.

Adjunct Stacks: Maximizing the Autonomic Reset Window

The SGB-induced sympathetic blockade creates a window of reduced catecholamine load. We find — and published case reports support — that this window is best leveraged with concurrent mitochondrial support to restore oxidative phosphorylation while sympathetic pressure is reduced:

• Mito-Resuscitation stack: CoQ10 (200-400 mg/day ubiquinol form) + NMN or NR for NAD+ repletion — supporting Complex I/II function and electron transport chain integrity. See our full breakdown in our post on mitochondrial health for professionals.
• Low-Dose Naltrexone (LDN): 1.5-4.5 mg nightly for microglial dampening and neuro-inflammation reduction. Full mechanistic review in our LDN and TRPM3 Long COVID post.
• Senolytics: Fisetin (500-1000 mg, pulsed 2 days on/5 days off) + Quercetin (500 mg/day) to clear SASP-driving senescent endothelial cells triggered by persistent spike protein remnants.

Comparison Table: Standard Autonomic Care vs. SGB + Emerging Protocol

Executive Takeaways: How Finance Professionals Should Frame This

For the banker or institutional professional evaluating this evidence, here is the risk-adjusted framing we recommend:

1. This is still an investigational intervention. The STAR-CO trial is the first RCT. No published RCT results exist yet. Evidence-based clinical practice requires waiting for that data before drawing definitive efficacy conclusions — though the signal from case series is sufficiently consistent to justify serious clinical evaluation for treatment-refractory POTS/Long COVID.
2. Procedure selection matters more than the decision to proceed. Ultrasound guidance is non-negotiable. An experienced interventional anesthesiologist or pain specialist with specific SGB training is mandatory. Do not accept a landmark-based technique in 2026.
3. Combine with systemic protocols. SGB addresses one node in a complex cascade. Without concurrent mitochondrial support, senolytic clearance of SASP-driving cells, and potentially neurological dampening via LDN, the procedure may produce temporary relief without addressing the underlying redox imbalance and bioenergetic failure perpetuating the condition.
4. Track your biomarkers pre- and post-procedure. Request morning catecholamine panels (norepinephrine, epinephrine), HRV (resting and 24-hour Holter), and a NASA Lean Test at baseline and 4 weeks post-SGB. This gives you an objective signal to calibrate further decisions.
5. This is re-optimization, not a cure. We frame this consistently: Long COVID is a systems failure, and recovery is a systematic re-engineering project with multiple intervention points, not a single-shot solution. Stellate ganglion block Long COVID POTS management is one lever in a larger protocol stack.

Conclusion: Where the Evidence Is Heading

The convergence of the STAR-CO trial registration, the Frontiers in Neuroscience editorial endorsement, and the growing case series literature means that stellate ganglion block Long COVID POTS is entering a new phase of clinical credibility. We are not at phase-3 RCT proof yet — but we are past the case-report-only stage. The mechanistic logic is solid: interrupt the catecholamine storm driving mitochondrial uncoupling, and you remove one of the primary drivers of bioenergetic failure in post-viral patients.

We will update this post when STAR-CO publishes results, expected in early-to-mid 2027. In the meantime, we recommend reviewing our related coverage on the photobiomodulation Long COVID brain fog RCT and the LDN TRPM3 Long COVID ion channel breakthrough — both addressing adjacent nodes in the same post-viral pathophysiological network.

⚠️ Medical Disclaimer: This article is written for educational and informational purposes only and does not constitute medical advice. Stellate ganglion block is an investigational procedure for Long COVID and POTS and has not been approved by the FDA for these indications. All interventions discussed — including SGB, LDN, senolytics, and mitochondrial supplement stacks — should be evaluated in consultation with a qualified physician who can assess your individual clinical situation. Never start, stop, or modify treatment based on information in this article. The STAR-CO trial results are not yet published; efficacy claims are based on preliminary case series and mechanistic rationale, not phase-3 RCT evidence.